-
CDK Related Products (486)
Related Products (486)
-
CDK1-IN-7
0 ImagesCat. No.: HY-176189CAS No.: 933009-51-9CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. CDK1-IN-7 inhibits the proliferation and migration of HCT116 and Lovo cells. CDK1-IN-7 can be used in the study of colorectal cancer.
-
CDK2-IN-14
0 ImagesCat. No.: HY-151580CAS No.: 2862836-22-2
-
Briciclib sodium
0 ImagesCat. No.: HY-16366ACAS No.: 865784-01-6Synonyms: ON 014185 sodiumBriciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors.
-
LQ23
0 ImagesCat. No.: HY-162398CAS No.: 2997615-62-8LQ23 is a selective inhibitor for CDC2-like kinase 2 (CLK2) with an IC50 of 1.4 nM. LQ23 exhibits anti-inflammatory activity.
![[pSer2, pSer5, pSer7]-CTD TFA](https://file.medchemexpress.com/product_pic/hy-p1933a.gif "Click to View [pSer2, pSer5, pSer7]-CTD TFA Product Detail")
-
CDK4-IN-2
0 ImagesCat. No.: HY-153443CAS No.: 2380320-68-1
-
CDK8-IN-9
0 ImagesCat. No.: HY-151255CAS No.: 2850253-95-9CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor with an IC50 value of 48.6 nM. CDK8-IN-9 can inhibit tumor growth and is used in colorectal cancer studies.
-
Cdc7-IN-9
0 ImagesCat. No.: HY-143380CAS No.: 2649407-21-4
-
PARP-1/2-IN-2
0 ImagesCat. No.: HY-149398CAS No.: 3052304-23-8
-
EGFR/HER2/CDK9-IN-2
0 ImagesCat. No.: HY-147797CAS No.: 1180924-34-8
-
CDK4/CycD2 Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70682CDK4 has a well-established role in cell-cycle controland CDK4-cyclin complexes are commonly deregulated in tumorigenesis. CDK4/CycD2 Recombinant Human Active Protein Kinase is an ortholog of CDK4.
-
CDK4/6-IN-13
0 ImagesCat. No.: HY-146214CAS No.: 1908454-70-5As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.
-
MPT0L145
0 ImagesCat. No.: HY-122888CAS No.: 2070837-24-8MPT0L145 is a PIK3C3/FGFR inhibitor, with a Kd value of 0.53 nM for PIK3C3. MPT0L145 decreases the phosphorylation of FGFR1, FGFR3 and their downstream proteins (FRS2, ERK and Akt). MPT0L145 induces G0/G1 cell cycle arrest and decreased protein levels of cyclin E. MPT0L145 promotes mitochondrial dysfunction, ROS production, and DNA damage. MPT0L145 is an autophagy inhibitor. MPT0L145 significantly sensitizes cancer cells to targeted or chemotherapeutic agents. MPT0L145 can be used for cancer research, such as bladder cancer and NSCLC.
-
VMY-1-101
0 ImagesCat. No.: HY-182383CAS No.: 1209002-42-5VMY-1-101 is a fluorescent cyclin-dependent kinase (CDK) inhibitor, with an excitation of 410 nm and emission of 512 nm. VMY-1-101 competitively inhibits ATP binding to CDKs. VMY-1-101 induces G2/M cell cycle arrest in human breast cancer cells. VMY-1-101 induces modest apoptosis in human breast cancer cells. VMY-1-101 blocks proliferation of human breast cancer cells, including multidrug resistance-positive cells, and is not a substrate for p-glycoprotein. VMY-1-101 localizes to the cytoplasm of human breast cancer cells. VMY-1-101 shows increased binding to human breast cancer tissue compared to fluorophore alone. VMY-1-101 can be used for the research of breast cancer.
-
CDK17/CycY Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70665CDK17 is highly expressed in terminally differentiated neurons, particularly those found in hippocampal regions and olfactory bulbs. CDK17/CycY Recombinant Human Active Protein Kinase is an ortholog of CDK17.
-
Anticancer agent 300
0 ImagesCat. No.: HY-181131CAS No.: 1310059-06-3Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
